Business Context and Reporting Period
This Form 8-K Current Report was filed by MacroGenics, Inc. (MGNX) on December 19, 2022. The report discloses a corporate governance event regarding the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
The material change disclosed is the appointment of Margaret Liu, M.D., to the Board of Directors, effective January 3, 2023. Dr. Liu has been designated as a Class II director and appointed to the Science & Technology Committee.
Compensatory Arrangements and Outlook
Dr. Liu's compensation package includes:
- An annual retainer consistent with the Company's Director Compensation Program.
- An option to purchase 36,000 shares of common stock at the closing market price on the Effective Date.
- Vesting over 36 substantially equal monthly portions, contingent on continued service.
The filing states there are no undisclosed arrangements or transactions in which Dr. Liu has a material interest. No financial guidance or risk factors specific to this appointment were disclosed.
Investor Verification Checklist
- Verify the effective date of Dr. Liu's appointment (January 3, 2023).
- Confirm the vesting schedule for the 36,000 share option grant.
- Review the Company's most recent proxy statement for details on the standard annual retainer for non-employee directors.
- Check the composition of the Science & Technology Committee following this appointment.